BioPharma Services USA Inc. Awarded a 5 Year – $20 Million USD Contract with the US FDA

COLUMBIA, MO.­­ (BUSINESS WIRE)­­ BioPharma Services USA, Inc. (BioPharma) is proud to announce that it has been awarded a 5­-year, $20 million contract with the Center for Drug Evaluation and Research

(CDER), a division of the US Food and Drug Administration (FDA). The contract is to conduct in vivo studies of generic drug products in human subjects over a period of five years, from 2016 through to 2021.

“We are very proud to work with the FDA in support of their Generic Drug programs. This award is a great example of BioPharma’s capabilities as a leading industry expert in Bioequivalence and Early Stage clinical research,” said Renzo DiCarlo, CEO at BioPharma Services, Inc.

The FDA studies conducted by BioPharma will allow CDER to proactively address scientific questions in developing generic approval standards and ensure post­market safety and efficacy of approved generic drug products. Ultimately, the outcome of these studies will help improve the generic review practice within CDER. As part of this contract, BioPharma will provide the FDA with a full service offering from study design inception to clinical conduct, bioanalysis and final report.

Brent Matthews, COO at BioPharma Services Inc. added: “I am certain that our outstanding regulatory history with the FDA and our team’s extensive expertise in the conduct of Bioequivalence trials played a major role in landing this important contract with the FDA.”

The statements in this press release are solely made by BioPharma and does not represent the official views of the FDA.

About BioPharma Services Inc.

BioPharma Services Inc. is a full­service Contract Research Organization (CRO) specializing in the conduct of Phase I/IIa and Bioequivalence clinical trials for international pharmaceutical companies worldwide. BioPharma has clinical facilities both in the USA and Canada with a total capacity of 250 beds with access to healthy volunteers, special populations and patients. Headquartered in Toronto, Canada, BioPharma’s comprehensive services also include Bioanalysis at our GLP Certified Laboratory, Scientific and Regulatory Affairs, Biostatistics and Safety Data Analysis, Medical Writing and Data Management.

Contacts

Main Telephone: 1 844 747 8484
Email: info@biopharmaservices.com
Website:  www.biopharmaservices.com

For more information regarding this press release, please contact:

BioPharma Services, Inc.
Ms. Anna Taylor
Vice President, Business Development
ataylor@biopharmaservices.com

Source: BioPharma Services, Inc.
View this news release online at: http://www.businesswire.com/news/home/20160520005856/en